Building C(sp3)-rich Complexity by Combining Cycloaddition and C–C Cross Coupling Reactions

Prized for their ability to rapidly generate chemical complexity by building new ring systems and stereocentres1, cycloaddition reactions have featured in numerous total syntheses2 and are a key component in the education of chemistry students3. Similarly, carbon–carbon (C–C) cross-coupling methods are integral to synthesis because of their programmability, modularity and reliability4. Within the area of drug discovery, an overreliance on cross-coupling has led to a disproportionate representation of flat architectures that are rich in carbon atoms with orbitals hybridized in an sp2 manner5. Despite the ability of cycloadditions to introduce multiple carbon sp3 centres in a single step, they are less used6. This is probably because of their lack of modularity, stemming from the idiosyncratic steric and electronic rules for each specific type of cycloaddition. Here we demonstrate a strategy for combining the optimal features of these two chemical transformations into one simple sequence, to enable the modular, enantioselective, scalable and programmable preparation of useful building blocks, natural products and lead scaffolds for drug discovery.Combining cycloaddition and carbon–carbon cross-coupling offers a way of simplifying the enantioselective preparation of chemical building blocks, natural products and medicines such as the antipsychotic asenapine.

[1]  E. Corey,et al.  Asymmetric Diels-Alder reactions catalyzed by a triflic acid activated chiral oxazaborolidine. , 2002, Journal of the American Chemical Society.

[2]  W. Price,et al.  Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. , 1991, Journal of medicinal chemistry.

[3]  Jonas Boström,et al.  Analysis of Past and Present Synthetic Methodologies on Medicinal Chemistry: Where Have All the New Reactions Gone? , 2016, Journal of medicinal chemistry.

[4]  Phil S. Baran,et al.  A General Alkyl‐Alkyl Cross‐Coupling Enabled by Redox‐Active Esters and Alkylzinc Reagents. , 2016 .

[5]  Phil S. Baran,et al.  Practical Ni-Catalyzed Aryl–Alkyl Cross-Coupling of Secondary Redox-Active Esters , 2016, Journal of the American Chemical Society.

[6]  Martin D. Eastgate,et al.  Decarboxylative Alkenylation , 2017, Nature.

[7]  T. Reid,et al.  Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer. , 2008, Future oncology.

[8]  H. Takaya,et al.  Iron-Catalyzed Suzuki—Miyaura Coupling of Alkyl Halides. , 2011 .

[9]  G. Bartoli,et al.  Asymmetric Cyclopropanation Reactions , 2014, Synthesis.

[10]  S. Chandrasekhar,et al.  The Ireland-Claisen rearrangement strategy towards the synthesis of the schizophrenia drug, (+)-asenapine. , 2016, Organic & biomolecular chemistry.

[11]  E. Corey,et al.  The Logic of Chemical Synthesis , 1989 .

[12]  Jun Guo,et al.  The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. , 2017, Nature chemical biology.

[13]  J. Yue,et al.  Attractive natural products with strained cyclopropane and/or cyclobutane ring systems , 2016, Science China Chemistry.

[14]  T. Bach,et al.  Recent Advances in the Synthesis of Cyclobutanes by Olefin [2 + 2] Photocycloaddition Reactions , 2016, Chemical reviews.

[15]  J. T. Njardarson,et al.  Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. , 2014, Journal of medicinal chemistry.

[16]  S. Bräse,et al.  Metal-catalyzed cross-coupling reactions and more , 2014 .

[17]  Ian Fleming,et al.  Frontier Orbitals and Organic Chemical Reactions , 1977 .

[18]  S. Bräse,et al.  Metal-catalyzed cross-coupling reactions and more , 2014 .

[19]  James R. Moore,et al.  Efficient Synthesis of Losartan, A Nonpeptide Angiotensin II Receptor Antagonist , 1994 .

[20]  Martin D. Eastgate,et al.  Decarboxylative Alkynylation. , 2017, Angewandte Chemie.

[21]  H. Takaya,et al.  Iron-catalyzed Suzuki-Miyaura coupling of alkyl halides. , 2010, Journal of the American Chemical Society.

[22]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[23]  K. Nicolaou,et al.  The Diels—Alder Reaction in Total Synthesis , 2002 .

[24]  Anna Tostevin,et al.  An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .

[25]  A. Padwa,et al.  Use of N-[(trimethylsilyl)methyl]amino ethers as capped azomethine ylide equivalents , 1987 .

[26]  Daniel M. Lowe,et al.  Big Data from Pharmaceutical Patents: A Computational Analysis of Medicinal Chemists' Bread and Butter. , 2016, Journal of medicinal chemistry.

[27]  H. Olivo,et al.  RECENT SYNTHESES OF EPIBATIDINE. A REVIEW , 2002 .

[28]  A. Ritzén,et al.  Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues. , 2001, Journal of the American Chemical Society.